anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: People living with HIV and non-communicable diseases (NCDs) are reported to experience challenges in accessing affordable and high-quality NCD care services. Consequently, the World Health Organization (WHO) recommends care integration of NCDs within the HIV services in resource-limited regions. The available opportunities and challenges need to be understood and addressed for an effective integration process. This study explored opportunities and challenges for integrating NCDs within HIV care and treatment services in Tanzania.
METHODS: An exploratory qualitative case study was conducted in Tanzania between April and July 2022. A total of 22 key informants working at the ministerial level, supervising the provision of healthcare services in Tanzania, were recruited purposefully for in-depth interviews. Thematic analysis was employed during the study.
RESULTS: Several opportunities were identified in the study for HIV/NCD services integration including the existence of an integration policy, the availability of regulations and guidelines, the existence of donor support, the presence of physical space and reliable information and communication systems, human resources adequacy, and political will to support the process. However, participants voiced concerns over the costs related to service integration, difficulties in reallocating donor funds, and hesitance of the healthcare providers as likely challenges to effective integration.
CONCLUSION: The findings of this study underscore that the effective and sustainable care integration of NCDs within HIV services relies on the availability of policy, funds, infrastructures, human resources, and stakeholders' willingness to support the process.
A nasal cavity spray agent for targeting, slow release, film forming and virus and bacteria inhibition and a preparation method thereof relate to the field of biology. The invention aims to solve the problems that the prior common film spraying agent: the targeted inhibition and killing of virus and bacteria can not be realized, the action time is short, the living environment of the virus can not be effectively isolated for a long time, and the virus replication inhibition efficiency is low. The invention adopts PVP to form a layer of soluble protective film and utilizes the slow release effect of CMC-NA. The living environment of the virus and the bacteria is effectively destroyed through a physical and biological double antibacterial mechanism, and the effects of resisting inflammation, inhibiting bacteria, isolating and killing virus microorganisms (including bacteria, viruses and the like) are achieved. By targeting agents of angiotensin 2 inhibitor and EDTA2Na, the dual advantages of a process prescription and a component mechanism combining targeting and sustained-release drug delivery are realized. The invention is applied to the field of medicine.
BACKGROUND: Associations of waist circumferences (WC) and body mass index (BMI) measured once or over time, with cancer incidence were studied. WC is associated with some cancers independent of BMI. Analyses of cumulative central adiposity and cancer are lacking. We investigated associations between waist circumference-years, incorporating exposure time to WC ≥ 102 cm in men or ≥88 cm in women, and cancer, and compared this with single WC or BMI.
METHODS: Serial WC measurements taken over 9 years in the prospective Atherosclerosis Risk in Communities Study (ARIC) predicted yearly WC. Cox proportional hazards regression estimated hazard ratios (HRs) of cancer incidence for waist circumference-years, WC or BMI, measured in Visit 4. Harrell's C-statistic quantified metric predictive performances.
RESULTS: 10,172 participants were followed up from Visit 4 for cancer over a median 13.7 for men and 15.8 years for women. For obesity-related cancers, HRs per standard deviation waist circumference-years were 1.14 (95%CI:1.04,1.25) and 1.19 (95%CI:1.12,1.27), respectively. Differences in metric predictive performances were marginal.
DISCUSSION: This is the first study to identify positive associations between waist circumference-years and cancer. Waist circumference-years did not provide additional information on cancer risk beyond that of WC and BMI. BMI is routinely measured in clinic so it may be preferred over WC.
Patients who were able to tolerate the treatment during the single-blind treatment run-in epoch. Following the run-in period, patients randomized in this arm were given valsartan at 160 mg twice daily for three years.
The invention protects a broad-spectrum anti-tumor mouse model prepared by the apoptosis corpuscle vaccine immunization, and the mouse is prepared by the apoptosis corpuscle vaccine immunization and has broad-spectrum anti-tumor property. The establishment method comprises the following steps: inducing cancer cell apoptosis in vitro by nutritional deficiency method to obtain apoptotic body. Kunming mice were immunized with apoptotic bodies once a week by subcutaneous injection of 25mg/kg apoptotic bodies per mouse for a total of five weeks. The results of in vivo antitumor experiments on mice show that the tumor inhibition rate of H22 tumor-bearing mice can reach 80.27 percent, and the molding success rate reaches 50 percent. The invention aims at the phenomena that in the existing immune anti-tumor animal experiment, the positive control modeling is unreasonable, and no broad-spectrum immune anti-tumor mouse exists in the market at present. The mouse immunized by the apoptotic bodies solves the problem, has stronger anti-tumor immunity, and has stable model and high production quality.
<P>PROBLEM TO BE SOLVED: To provide lipid:nucleic acid complexes that have increased shelf life and high transfection activity in vivo following intravenous injection, and to provide methods of preparing such complexes.  <P>SOLUTION: The methods generally comprise contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid:nucleic acid complex. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fab' fragment attached to a hydrophilic polymer. Further provided are lipidic microparticles with attached proteins which have been conjugated to linker molecules having a hydrophilic polymer domain and a hydrophobic domain capable of stable association with the microparticle, or proteins which have been engineered to contain a hydrophilic domain and a lipid moiety permitting stable association with the microparticle.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The study reported a woman with syndrome of repeated oocyte maturation failure where there is repeated production of immature oocytes.She underwent two IVF cycles in other hospital. All oocytes obtained were immature and the treatment were stopped.She underwent her third try in our hospital. The couple gave their informed consent: ICSI will be performed if maturation occurred, otherwise, the treatment would be stopped and the oocytes would be donated for study if the oocytes were not matured after 24 hours of culture. After ovarian hyperstimulation,14 oocytes were obtained. None of them was matured. The cycle was canceled and the oocytes were donated for study.To induce the immature oocytes in vitro, oocytes were 1)cultured in follicular fluid containing matured metaphase II oocyte; 2) performed intracytoplasmic sperm injection (ICSI) to induce intracellular Ca2+\]i oscillations; 3)injected with active maturation promoting factor (MPF), 4)injected with cytoplasm of matured metaphase II oocyte.
The aim of this study is to formally evaluate whether the investigators can indeed prevent HO by the timely and painless use of CPM in neurogenic intensive care unit (ICU) patients with stabilized medical conditions, suffering from neurological insults either traumatic brain injury (TBI), stroke, or Spinal Cord Injury (SCI). The investigators hypothesize that HO formation can be suppressed if CPM can be performed for a substantial amount of time. The investigators will perform a pilot study with 10 ICU patients receiving CPM and 10 matched cases which will follow a conventional physiotherapy program at the time of the conduction of the study. The primary outcomes will be the CT appearance of HO in the hip or knee joint and the degree of ROM limitation in the given joint at baseline and at the end of the clinical trial. A secondary outcome that will be measured, will be the Glasgow Coma Scale (GCS) at the beginning and at the end of the CPM program. The comparison between the treatment and referent groups in terms of these outcomes will prove the prophylactic power of CPM against HO.
STUDY DESIGN: A retrospective study.
OBJECTIVE: The aim of this study was to compare clinical and radiological outcomes of the anterior cervical discectomy and fusion (ACDF) with a novel zero-profile variable-angle (Zero-P VA) spacer and a traditional poly-ether-ether-ketone (PEEK) cage and plate system in cases pertaining to cervical radiculopathy/myelopathy. There are two conventional types of ACDF procedures aimed at treating symptomatic cervical spondylosis. The first one involves an uninstrumented "stand-alone" approach utilizing bone graft/cage, while the second incorporates bone graft/cage in conjunction with a front plate positioned before the vertebral bodies. Both procedures have their own inherent advantages and disadvantages. The Zero-P VA spacer, however, represents a unique synthesis by amalgamating the advantages of both traditionally typical procedures. Notably, this spacer can potentially circumvent the issue related to prevertebral soft-tissue disturbance and reduce the occurrence of dysphagia.
METHODS: Using our surgical database, the authors systematically conducted a retrospective analysis encompassing all patients who underwent single-level ACDF between January 2018 and January 2019, with a minimum two-year follow-up. Patients either received a Zero-P VA implant or PEEK cage coupled with plating. The Japanese Orthopedic Association (JOA) score and Visual Analogue Scale (VAS) for arm and neck pain were documented. Dysphagia was evaluated using the Eating Assessment Tool-10 (ETA-10). Additional parameters such as cervical alignment, fusion rate and the incidence of postoperative complications were assessed.
RESULTS: According to the outcomes of the statistical analysis, there was no substantial disparity that emerged in the advancements observed in the JOA and VAS metrics between the two study cohorts. Noteworthy, however, the ETA-10 scores were statistically significantly reduced in the Zero-P VA group compared to the cage and plating group (p < 0.05). At the final follow-up, there were no statistically significant differences in the height of the operated segment, Cobb angle of the fused segment, C2-C7 Cobb angle and fusion rate between the two groups (p > 0.05). However, postoperative complications were slightly lower in patients with the Zero-P VA group (7.69%) as compared to the cage and plating group (16.67%).
CONCLUSION: The clinical outcomes observed with the Zero-P VA spacer used for single-level ACDF were found to be satisfactory. The performance of this device is comparable or even superior to the traditional cage and plating method in preventing postoperative dysphagia and mitigating potential complications associated with the use of a plate.
1,185,076. Monoaminobisthiosemicarbazones. FARBWERKE HOECHST A.G. 15 May, 1967 [14 May, 1966], No. 22426/67. Heading C2C. Novel compounds of formula wherein. R is dimethylamino or diethylamino, are prepared by reaction of a compound of formula with a compound of formula or by reaction of a compound of formula with a compound of formula or by reaction of a mustard oil of formula S=C=N-CH 2 -CH 2 -R with a compound of formula or by reaction of a mustard oil of formula with a compound of formula Diacetyl - mono (2 - dimethyaminoethyl - thiosemicarbazone)-monohydrazone is prepared by reaction of equimolar quantities of diacetyl-dihydrazone and dimethylaminoethyl mustard oil. Diacetyl - mono(2 - diethylaminoethyl - thiosemicarbazone)-monohydrazone is prepared either by reaction of equimolar quantities of diacetyldihydrazone and diethylaminoethyl mustard oil or of diacetyl monohydrazone monoxime and 2-diethylaminoethyl-thiosemicarbazide. Compositions having anti-coccidiosis activity and being in forms suitable for oral administration, for example, in food mixes, comprise an above novel compound and a carrier which may also contain vitamins and growth promotants such as antibiotics.
The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgingival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients has prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
Recently, the validity and reliability of assessment tools in which two tasks are performed simultaneously have been investigated. Although the utility of dual-task assessments in assessing falls in neurological diseases is uncertain, the reliability of dual-task assessments involving walking has shown quite good results. Stroke survivors have decreases in one or both (locomotor and cognitive) performances while walking and simultaneously performing a cognitive task. The tasks selected in dual-task evaluations may affect dual-task interactions, therefore, tasks that are compatible with daily living activities should be used in dual-task evaluations. A previous study confirmed the validity of the dual-task F8W test in predicting falls in older adults. Because of this reaason, stroke patients aged 50 and over will be included in the study.
The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
Participants randomized to the "Immediate" or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time).
Participants will be outfitted with a virtual reality headset. While seated in a recliner chair, participants will engage in a pre-specified VR nature experience called Nature Treks VR for 5 minutes.
The application of near infrared heavy atom-free BODIPY in photodynamic therapy of metastatic tumor and up-conversion belongs to the field of fine chemical engineering and life medicine. The structure of the reagent parent and the nano particles thereof have excellent photodynamic treatment effect. The nanoparticles are combined with immune drugs, and the outstanding effect of treating the metastatic tumor is verified by a tumor animal model. The photosensitive molecules are simple to synthesize and low in cost, have strong absorption capacity in a long wavelength region, have ultra-long triplet state service life and high triplet state quantum yield. In view of the excellent performance of the photosensitive molecules, the molecules are expected to become a new generation of photodynamic therapeutic reagent and metastatic tumor therapeutic reagent in clinic. In addition, the invention also relates to a pure organic up-conversion system without heavy atoms, and because the used photosensitive molecules have strong light absorption capacity, the red light can be converted into extremely bright yellow up-conversion luminescence, so that the invention has great application potential in the biological field.
The invention discloses a chitosan water-soluble composition and a use thereof. The chitosan water-soluble composition comprises, by mass, 10 to 70 parts of chitosan, 30 to 90 parts of a succinic acid composition and 0.01 to 5 parts of essence. The essence comprises one or more of natural essence, natural essence analogues and synthetic essence. A degree of deacetylation of the chitosan is greater than 50%. The purity of the succinic acid composition is greater than 90%. Preferably, a degree of deacetylation of the chitosan is greater than 80%. The chitosan water-soluble composition can be dispersed in water to form a chitosan composition aqueous solution. The chitosan composition aqueous solution can be used in fields of air purification, bacteriostasis, moisture retention, dust prevention, preservation, water purification, cosmetics and foods.
Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment, fibroblasts are cultured in an acidic pH incubation medium before genetic modification, after genetic modification, or both. In another embodiment, fibroblasts are cultured under hypoxic conditions. In another embodiment, fibroblasts are treated with mitogenic factor-comprising composition(s) to increase the efficacy of genetic modification, wherein the mitogenic factor(s) may be cytokines, peptides, and/or proteins. In another embodiment, a therapeutically effective amount of the genetically modified fibroblasts are provided as a therapeutic application to an individual in need thereof. In another embodiment, the therapeutic application is treatment of fibrosis, treatment of inflammation, acceleration of healing, treatment of clotting disorders, or promotion of angiogenesis.
This trial is designed as a multicentre, phase II, open-labeled, multi-arm, single intravenous (IV) dose study. The patient is to receive general anesthesia. WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 4 or 6 mg/kg using 753nm laser light at a fixed power (150 mW/cm or 200 mW/cm or 250 mW/cm ) and light energy (200 J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
The 12-week intervention will consist of 9 modules and 2 optional modules that will be delivered to patients in the active intervention via a platform or app. Psychologists will provide asynchronous guidance via the platform. Motivational interviewing will be used during the intervention to prevent dropout. The psychologist may contact patients via telephone during the intervention if needed. All patients will have access to the intervention up to 6 months' post intervention so that they can revisit the material and reuse it on a need-to-basis. Patients will be recommended to use this option and to note specific time points in their agenda where they will access the intervention. A brief purpose-designed interview protocol that includes elements from the SCAN interview will be carried out by psychologists trained in conducting the interview.
PURPOSE: An apparatus and a method for extracting prickly pear emulsion are provided to easily extract emulsion and to eliminate remaining impurities after the extraction of the emulsion by arranging prickly pear materials in a stainless steel net. CONSTITUTION: An apparatus for extracting prickly pear emulsion includes a heating container housing(10), a heater line(20), a first heat supplying boiler(30), a heater core(40), a second heat supplying power part(50), a second heat supplying rotating part(60), a stainless steel net(70), a storing container housing(80), and a filter(90). Prickly pear is temporarily stored in the heating container housing. The heater line heats the heating container housing. The first heat supplying boiler supplies warm water to the heater line. The heater core heats the inside of the heating container housing at a constant temperature. The second heat supplying power part supplies electricity to the heater core. The second heat supplying rotating part rotates the heater core and uniformly heats the inside of the heating container housing.
Renal impairment can significantly alter the disposition of tolterodine immediate release and its metabolites. In a study conducted in patients with creatinine clearance between 10 and 30 mL/min, tolterodine and 5-HMT levels were approximately 2–3 fold higher in patients with renal impairment than in healthy volunteers. Exposure levels of other metabolites of tolterodine (e.g., tolterodine acid, N-dealkylated tolterodine acid, N-dealkylated tolterodine, and N-dealkylated hydroxy tolterodine) were significantly higher (10–30 fold) in renally impaired patients as compared to the healthy volunteers. The recommended dose for patients with severe renal impairment (CCr: 10–30 mL/min) is DETROL LA 2 mg daily. Patients with CCr<10 mL/min have not been studied and use of DETROL LA in this population is not recommended [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.6)]. DETROL LA has not been studied in patients with mild to moderate renal impairment [CCr 30–80 mL/min].